Independent Review of the 68th Annual AASLD

About the Program

• Program Overview
• Target Audience
• Learning Objectives
• Course Director and Moderator
• Faculty
• Physician Continuing Medical Education
• Disclosure of Conflicts of Interest
• Instructions For Participation and Credit
• Disclosure of Unlabeled Use
• Poster Presentation Listing
  
• Disclaimer

Program Overview

The Advances in Chronic Hepatitis C: Management and Treatment program is a comprehensive, expert review of the 68th American Association for the Study of the Liver Diseases Annual Meeting (AASLD 2017). This program will feature HCV experts reviewing and discussing the most important studies on chronic hepatitis C presented at AASLD 2017. This review and discussion will provide a comprehensive overview of each of the posters and presentations as selected by our faculty panel. In addition, the faculty will provide unique insights into how knowledgeable experts review and analyze data from AASLD and an in-depth understanding of the scientific quality and clinical relevance of the posters and presentations reviewed.

This activity will enable participating health care providers caring for HCV-infected patients to become aware of and understand the data presented at this important conference and appropriately utilize those data to improve patient care.

Back to Top   

Back to Top

After completing this activity, the participant should be better able to:

• Use in a clinical setting important findings from key studies on CHC diagnosis and treatment presented at AASLD 2017 

• Employ the current treatment paradigms for CHC, including the studies and data presented at AASLD 2017, to improve patient care

• Discuss with patients and colleagues the studies and data on newer therapies for CHC presented at AASLD 2017 to decide on appropriate planning of therapy for patients with CHC

Release Date:  November 1, 2017

Expiration Date:  November 1, 2018

Estimated time to complete this program: 15-30 minutes per module

Media: Internet

Back to Top

Course Director

Mark Sulkowski, MD
Professor of Medicine and Medical Director
Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Faculty

Nezam H. Afdhal, MD
Professor of Medicine
Harvard School of Medicine
Chief of Hepatology, Director of Liver Center
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Fred Poordad, MD
VP, Academic and Clinical Affairs
The Texas Liver Institute
Clinical Professor of Medicine
University of Texas Health Science Center
San Antonio, Texas

Jürgen Rockstroh, MD
Professor of Medicine
Department of Medicine I
University Hospital
Bonn, Germany 

Back to Top  

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. There will be 8 posters and presentations available for a total of 2.00 possible credit hours.

Back to Top

Disclosure of Conflicts of Interest

• Consulting Fees: Merck, Gilead, Echosens, Ligand, Janssen, Shionogi
• Employee/Salary: Sprint Bank Pharmaceuticals (Research Company)
• Other: Director-TRIO Healthcare
• Stock: Allurion, Spring Bank Pharmaceuticals
• Stock Options: SpringBank Pharmaceuticals, TRIO

Fred Poordad, MD

• Consulting Fees: Abbvie, Gilead, Merck, BMS, Salix
• Fees for Non-CME/CE Services Received Directly from a Commercial Interest or thier Agents: Abbvie, Gilead, Merck, BMS, Salix
• Research Support: Abbvie, Gilead, Merck, BMS, Salix

Juergen Rockstroh, MD

• Consulting Fees: Abbott, Gilead, Hexal, Merck, ViiV
• Fees for Non-CME/CE Services Received Directly from a Commercial Interest or thier Agents: Abbott, Gilead, Janssen, Merck
• Contracted Research: Gilead

Mark Sulkowski, MD

• Contracted Research (to JHU): Abbvie, Gilead, Merck, Tobira
• Consulting Fees: Abbvie, CoCrystal, Gilead, Janssen, Merck, Trek
• Other: Gilead - DSMB Member

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Back to Top

Poster/Presentation Listing

	Survival Benefit of Direct-Acting Antiviral Therapy in Patients with Decompensated Cirrhosis
	Current DAAs Including Treatment of DAA Non-Responders and RASs
	Impact of Sustained Virologic Response with Direct-Acting Antiviral Treatment on Mortality and Hepatocellular Carcinoma
	Significant and Sustained Improvement of Health-Related Quality of Life Scores in Patients with Hepatitis C and Sustained Virologic Response
	100% SVR with 8 Weeks of Ledipasvir/Sofosbuvir in HIV-infected Men with Acute HCV Infection: Results from the SWIFT-C Trial
	C-BREEZE-1, C-BREEZE - 2 and OMEGA-1 Studies
	Cure Denied and Cure Delayed in Chronic Hepatitis C; Monitoring Non-start Rates and Increased Time to Start Using Real-world Data from the TRIO Network
	The Impact of Hepatitis C Diagnosis on Substance-use Behaviors in Patients Engaged in Opioid Substitution Therapy

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. 

Back to Top